iiinova — where your digital self keeps evolving

Boehringer Ingelheim @boehringerglobal.bsky.social · 01/10/2026

#NEWS: Phase III trial data for people living with #obesity, overweight & #T2D were presented today at @easdnews.bsky.social These results will help us understand how survodutide can provide weight loss benefits whilst improving blood sugar levels. 👉 go.boehringer.com/SBqTr #LifeForward #EASD2026

110

Boehringer Ingelheim @boehringerglobal.bsky.social · 23/09/2026

#NEWS: We have launched a new Stop Rabies project in Zimbabwe together with AWARE. By combining dog vaccination, population management and community education, we aim to help reduce the burden of rabies in Tsholotsho District and protect both people & animals. 👉 go.boehringer.com/5nGQ #StopRabies

010

Boehringer Ingelheim @boehringerglobal.bsky.social · 01/09/2026

#News: We’re launching SCOVELLA® in GB, the first licensed therapy to treat hyperinsulinaemia in insulin-dysregulated horses. It addresses the main cause of laminitis, one of the most devastating diseases affecting horses. www.boehringer-ingelheim.com/animal-healt... #AnimalHealth

000

Boehringer Ingelheim @boehringerglobal.bsky.social · 11/08/2026

#NEWS: We have acquired Evax AG, a Swiss company developing therapeutic vaccines for horses. The acquisition complements our work with virus-like particle technology & opens new opportunities for innovation in equine health. Learn more: www.boehringer-ingelheim.com/partnering/a... #EquineHealth

000

Boehringer Ingelheim @boehringerglobal.bsky.social · 17/07/2026

#NEWS: The @ec.europa.eu has granted marketing authorization for our treatment of adults with idiopathic pulmonary fibrosis (IPF) and adults with progressive pulmonary fibrosis (PPF). Learn more: www.boehringer-ingelheim.com/human-health... #LifeForward #PulmonaryFibrosis

000

Boehringer Ingelheim @boehringerglobal.bsky.social · 16/07/2026

#NEWS: Phase II trial initiated for our investigational triple receptor agonist for #obesity. This trial will help drive understanding of both biological and behavioural drivers of obesity to improve health outcomes. Read more 👉 go.boehringer.com/oxr1a #LifeForward

000

Boehringer Ingelheim @boehringerglobal.bsky.social · 07/06/2026

#NEWS: Full data from two Phase III trials in people living with #obesity presented at #ADA2026. These results show potential to address patients’ unmet needs in obesity and liver health. Read more 👉 go.boehringer.com/4hch #LifeForward #ADASciSessions

110

Boehringer Ingelheim @boehringerglobal.bsky.social · 30/05/2026

Lung cancers are not all the same. For some, a HER2 (ERBB2) gene mutation is what is driving it. Biomarker testing identifies what’s behind each person’s cancer, giving care teams critical information to help inform clinical decisions. Learn more: bit.ly/4nUyHXq #LifeForward #Oncology #LungCancer

010

Boehringer Ingelheim @boehringerglobal.bsky.social · 27/05/2026

#NEWS 🧪87% of pet vets say spotting hidden health problems is the most critical yet overlooked part of their job. New global findings from 1,000+ vets across 51 countries reveal what's really being missed – and why it matters for animals, food safety and public health👉 go.boehringer.com/Gy8CU

042

Boehringer Ingelheim @boehringerglobal.bsky.social · 22/05/2026

#NEWS: The CHMP of @ema.europa.eu has issued a positive opinion for our medicine in #IPF and #PPF – a major milestone in the EU review process and a step forward for people living with these serious lung diseases. Learn more: go.boehringer.com/XxUd #LifeForward #PulmonaryFibrosis

010

Boehringer Ingelheim @boehringerglobal.bsky.social · 22/05/2026

#NEWS: Our targeted therapy has received approval in China as a first-line treatment for adults with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), making it an initial therapy option. 🧪Learn more: go.boehringer.com/_xdMW #LifeForward #Oncology #LungCancer

110

Boehringer Ingelheim @boehringerglobal.bsky.social · 21/05/2026

#NEWS: New data in NSCLC, SCLC and extrapulmonary neuroendocrine carcinoma will be presented at #ASCO26, adding to our growing body of research on targeted approaches in difficult-to-treat cancers. Learn more: go.boehringer.com/UfRlZ #LifeForward #Oncology

000

Boehringer Ingelheim @boehringerglobal.bsky.social · 18/05/2026

#NEWS: Japan’s MHWL has approved our treatment for #IPF and #PPF. Both conditions cause rapid lung-function loss, with severe quality-of-life impacts and claim many lives within just a few years of diagnosis. 🧪Learn more: go.boehringer.com/xZhV

030

Boehringer Ingelheim @boehringerglobal.bsky.social · 12/05/2026

#NEWS Today, we announced a global licensing deal w/ Immunitas Therapeutics to advance a preclinical antibody for inflammatory & autoimmune diseases. It selectively targets pathogenic immune cells at inflammation sites, w/ potential for more durable control. 🧪Learn more: go.boehringer.com/1zNK7

Quote by Carine Boustany, Global Head of Immunology and Respiratory Diseases at Boehringer Ingelheim, saying: "This distinct program aims to step up where current treatments fall short."

010

Boehringer Ingelheim @boehringerglobal.bsky.social · 29/04/2026

#NEWS: Together with Eko Health Inc., we’re launching an AI based solution to detect, visualize and grade heart murmurs in dogs. Eko Vet+™ | CANINEBEAT® AI supports veterinarians in identifying murmurs that may otherwise go unnoticed. Learn more: go.boehringer.com/6EMA5 #VetTech #LifeForward

011

Boehringer Ingelheim @boehringerglobal.bsky.social · 28/04/2026

#NEWS: Our Phase III trial in people living with #obesity or overweight without type 2 diabetes has met its co-primary endpoints. Obesity is linked to liver disease, type 2 diabetes and cardiovascular disease. Read more 👉 go.boehringer.com/Nsw9 #LifeForward

010

Boehringer Ingelheim @boehringerglobal.bsky.social · 13/04/2026

#NEWS: We’re launching a new vaccine to help prevent mastitis, one of the most common diseases in dairy cows. Designed for a two-dose administration, it offers early and long‑lasting protection. Learn more here: go.boehringer.com/m8oFO #LifeForward

010

Boehringer Ingelheim @boehringerglobal.bsky.social · 09/04/2026

Rabies is fatal once symptoms appear – but it’s preventable. Supported by our Stop Rabies program, Ecuador is accelerating efforts to eliminate dog‑mediated rabies by 2030 through vaccination, education and stronger surveillance. Read more 🧪👉 go.boehringer.com/HlQ7Y #OneHealthSummit #LifeForward

092

Boehringer Ingelheim @boehringerglobal.bsky.social · 25/03/2026

#PRESS: In 2025, we accomplished significant milestones together; we… 👉 reached more patients with our therapies than ever before 👉 invested a record EUR 6.4 bn in R&D 👉 made strong progress across Human Pharma & Animal Health with new launches and vaccines 🧪➡️ go.boehringer.com/1HN8D

072

Boehringer Ingelheim @boehringerglobal.bsky.social · 18/03/2026

#NEWS: Our global survey reveals that pet owners lack awareness of parasite risks. 43% of pet owners report parasite infections and 75% want clearer prevention advice. Read more 👉 go.boehringer.com/4yoE #vetmed #PublicHealth 🧪

220

Boehringer Ingelheim @boehringerglobal.bsky.social · 26/02/2026

#NEWS: Today, the @fda.gov approved our orally administered therapy for patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) as an initial treatment. This marks the first approved targeted therapy for this use. Learn more: go.boehringer.com/VHCH- #LifeForward

040

Boehringer Ingelheim @boehringerglobal.bsky.social · 28/01/2026

#NEWS: New Phase II trial results in primary focal segmental glomerulosclerosis (FSGS) published in The Lancet. Primary FSGS is a rare, progressive kidney disease, which can end in kidney failure. Read more 👉 go.boehringer.com/VecpO #LifeForward

010

Boehringer Ingelheim @boehringerglobal.bsky.social · 27/01/2026

#NEWS: Advancing a promising bispecific antibody for inflammatory bowel disease This innovative approach with Simcere targets two pathways in one molecule - aiming to improve outcomes for patients living with this lifelong, progressive condition. 🧪 Learn more: go.boehringer.com/VUcXm

020

Boehringer Ingelheim @boehringerglobal.bsky.social · 19/12/2025

#NEWS: The @fda.gov has approved our new treatment for progressive pulmonary fibrosis (PPF) in adults. The approval provides hope to people living with this life-threatening condition. Learn more here: go.boehringer.com/SYRTX #LifeForward #PulmonaryFibrosis

020

Boehringer Ingelheim @boehringerglobal.bsky.social · 11/12/2025

Understanding and treating HER2driven lung cancer is a critical need. In collaboration with the @lcrf.org, we’re proud to congratulate three early career investigators, each receiving a two-year, $250K grant, to advance HER2mutated lung cancer research. Learn more here: LCRF.org/251209bi

lcrf.org

Announcing the 2025 LCRF | Boehringer Ingelheim Early Career Investigator Awards - Lung Cancer Research Foundation

Three grants awarded for projects focused on HER2-driven lung cancer NEW YORK, NY (December 9, 2025) – The Lung Cancer Research Foundation (LCRF), in collaboration with Boehringer Ingelheim, grants tw...

000

Boehringer Ingelheim @boehringerglobal.bsky.social · 11/12/2025

Dr. Adrian Krainer received the Heinrich Wieland Prize for his pioneering contributions to #RNA research, leading to the first therapy for spinal muscular atrophy (SMA). He recently visited our R&D site to share some insights. Discover our research culture: go.boehringer.com/z1-T #medsky #pharmsky

Researcher and winner of the Heinrich Wieland Prize Dr. Adrian Krainer is smiling into the camera. There is a quote saying "It warms my heart to see our research turn into a drug that saves lives."

000

Boehringer Ingelheim @boehringerglobal.bsky.social · 10/12/2025

#NEWS: China’s National Medical Products Administration (NMPA) has approved our new treatment for progressive #PulmonaryFibrosis (PPF). 🧪 In a field where milestones are scarce, today signals meaningful momentum for the PPF community. Learn more: go.boehringer.com/ao0kp #LifeForward

010

Boehringer Ingelheim @boehringerglobal.bsky.social · 10/11/2025

#NEWS: Our investigational targeted therapy has been awarded a Commissioner’s National Priority Voucher from the U.S. FDA. Find out more here go.boehringer.com/Fyr8N #LifeForward #Oncology

101

Boehringer Ingelheim @boehringerglobal.bsky.social · 04/11/2025

#NEWS: 🧪 Building on our partnership in geographic atrophy, we’re launching a new collaboration with @cdr-life.bsky.social. Our aim is to advance antibody-based therapies for autoimmune diseases, such as lupus, multiple sclerosis and arthritis. Read more: go.boehringer.com/FOSjl

051

Boehringer Ingelheim @boehringerglobal.bsky.social · 30/10/2025

#NEWS: We’ve acquired a pre-clinical program from Kyowa Kirin to develop small molecules targeting autoimmune diseases. Our aim is to address the root cause of these conditions and deliver long-lasting therapies. 🧪 Learn more: go.boehringer.com/MPRF #Innovation #AutoimmuneDiseases #PharmSky

Boehringer acquires new pre-clinical program targeting autoimmune diseases.

111

Boehringer Ingelheim @boehringerglobal.bsky.social · 22/10/2025

#NEWS: The National Medical Products Administration (NMPA) in China has approved our new treatment for idiopathic pulmonary fibrosis (#IPF). 🧪 Learn more here: go.boehringer.com/HdX1

011

Boehringer Ingelheim @boehringerglobal.bsky.social · 20/10/2025

The immune system has the remarkable ability to identify and eliminate cancer cells. Our oncology research includes the investigation of T-cell engagers, focusing on leveraging immune mechanisms in cancer therapy. Learn more 🧪: go.boehringer.com/Ki82v #LifeForward #Oncology

061

Boehringer Ingelheim @boehringerglobal.bsky.social · 17/10/2025

#NEWS: Our latest oncology research in HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) has been presented at #ESMO25. These advancements have the potential to fulfill patients’ unmet needs. 🧪 Find out more: go.boehringer.com/FU9K9 #LifeForward #Oncology

020

Boehringer Ingelheim @boehringerglobal.bsky.social · 16/10/2025

Living with cancer, the small, positive moments often have the biggest impact. We're here to celebrate these 'Big Little Things': small victories, time with loved ones, and everyday joys. 🧪 Discover how these moments make a difference: go.boehringer.com/YomJY #LifeForward #Oncology

020

Boehringer Ingelheim @boehringerglobal.bsky.social · 10/10/2025

#NEWS: Ten of our oncology abstracts will be presented at #ESMO25, sharing our ongoing research efforts in hard-to-treat cancers. 🧪 Learn more: go.boehringer.com/GCZ1 #LifeForward #Oncology

020

Boehringer Ingelheim @boehringerglobal.bsky.social · 09/10/2025

#NEWS:  The U.S. Food and Drug Administration (FDA) has approved the first new treatment for idiopathic pulmonary fibrosis (#IPF) in over a decade. 🧪 Learn more here: go.boehringer.com/rtx-w #LifeForward

073

Boehringer Ingelheim @boehringerglobal.bsky.social · 29/09/2025

#NEWS: New pooled phase III data in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) presented at the European Respiratory Society (ERS) Congress 2025: go.boehringer.com/rdYYD 🧪 #ERS2025 #LifeForward

031

Boehringer Ingelheim @boehringerglobal.bsky.social · 09/09/2025

#NEWS: Our targeted cancer therapy for advanced non-small cell lung cancer (NSCLC) received Breakthrough Designation for first line use in the U.S. 🧪 Find out more here: go.boehringer.com/dz4O

040

Boehringer Ingelheim @boehringerglobal.bsky.social · 08/09/2025

#NEWS: New data available in HER2 (ERBB2)-mutant non-small cell lung cancer (NSCLC) in patients with stable, asymptomatic, and active brain metastases – underscoring our commitment to patients’ greatest needs.  🧪 Learn more about our presentation at #WCLC25: go.boehringer.com/WdAhL

050

Boehringer Ingelheim @boehringerglobal.bsky.social · 02/09/2025

We’re joining forces with @www.helmholtz-munich.de to drive new advances in fibrotic lung disease research. As leaders in fibrotic lung disease, we’re pioneering new therapies and striving towards our ultimate goal of finding a cure 🧪 Learn more: go.boehringer.com/HP-j5 #LungHealth #IPF

030

Boehringer Ingelheim @boehringerglobal.bsky.social · 01/09/2025

#NEWS for media: Our targeted cancer therapy has received approval in China for use in previously treated people with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC). 🧪 Learn more here: go.boehringer.com/YrIQ #LifeForward #Oncology

000

Boehringer Ingelheim @boehringerglobal.bsky.social · 18/08/2025

#NEWS: We are further strengthening our commitment to vision preservation by teaming up with Palatin Technologies. This partnership aims to develop a new first-in-class treatment for diabetic retinopathies. 🧪 Learn more: go.boehringer.com/py5Iu #EyeHealth #DiabeticRetinopathy #Innovation

020

Boehringer Ingelheim @boehringerglobal.bsky.social · 15/08/2025

At 37, Samantha was diagnosed with non-small cell #lungcancer (NSCLC). With support from her husband Justin and care team, she learned about #biomarker testing 🧪 to understand her cancer’s unique profile. #LifeForward #Oncology #Medsky

0111

Boehringer Ingelheim @boehringerglobal.bsky.social · 08/08/2025

#NEWS for media: Our targeted cancer therapy has been approved in the U.S. for people with HER2 (ERBB2)-mutant advanced non-small cell lung cancer by the U.S. @fda.gov‬. Learn more here 👉: www.boehringer-ingelheim.com/human-health... #LifeForward #Oncology

020

Boehringer Ingelheim @boehringerglobal.bsky.social · 07/08/2025

#NEWS: With Click Therapeutics, we’re excited to announce our Phase III clinical study in people with experiential negative symptoms of schizophrenia met its primary endpoint. This is an important step forward in advancing mental health care 🧪. Learn more: go.boehringer.com/cvjNF

040

Boehringer Ingelheim @boehringerglobal.bsky.social · 24/07/2025

#NEWS: First Half of 2025 👉 EUR 14.0 billion in group net sales 👉 Zongertinib in #oncology and nerandomilast in #pulmonaryfibrosis near launch 👉 #AnimalHealth business grew by 7.6% 👉 Fast-growing pipeline in cardio-renal-metabolic diseases Learn more ➡️ go.boehringer.com/w7ce3

H1 Results of Boehringer Ingelheim: Growth and pipeline progress

020

Boehringer Ingelheim @boehringerglobal.bsky.social · 10/06/2025

#NEWS: We’re kicking off a new chapter in digital health through our collaboration with Eko Health to improve heart murmur detection in dogs. We will bring an AI-powered tool to veterinarians to give dogs and pet owners more years of life to love. 🐕 #LifeForward Learn more: go.boehringer.com/4olwa

010

Boehringer Ingelheim @boehringerglobal.bsky.social · 22/05/2025

#NEWS: Tackling cardiovascular, renal and metabolic conditions together may be the key to hitting the UN’s 2030 goal of cutting early deaths from #NCDs by a third. Explore how 16 countries are tackling these challenges in the global Future Health report, launched at #WHA78. 👉 bit.ly/4jeQ6WZ

010

Boehringer Ingelheim @boehringerglobal.bsky.social · 19/05/2025

#NEWS: Pivotal FIBRONEER™-IPF and FIBRONEER™-ILD phase III full data in IPF and PPF presented at #ATS2025 and published in @nejm.org. IPF and PPF are serious conditions that can cause irreversible lung damage and continued decline in lung function. 🧪 👉 go.boehringer.com/1fG0l #LifeForward

033

Boehringer Ingelheim @boehringerglobal.bsky.social · 14/05/2025

#NEWS: We are joining forces with @tempusai.bsky.social By combining our experimental data with Tempus AI's real-world data on its AI-powered platform, we aim to pave the way for novel cancer treatments. Learn more: bit.ly/43owlqa #DataScience #Cancer #ResearchCollaboration

A young man shows a tablet screen to an older man. The headline says "Progressing cancer care." and on the bottom right "Life forward".

131